• Wondering if ArriVent BioPharma at around US$22.86 is offering fair value, or if the market is missing something in this biotech story?
• The stock has had a mixed run, with a 5.1% decline over the last week, a 0.4% return over the past month, and a 9.9% gain year to date, contributing to a 17.0% return over the last year.
• Recent attention on ArriVent BioPharma has centered on its position within the biotech space and how its pipeline prospects and funding profile compare with peers. This context has helped shape how investors interpret the recent share price moves and the balance between growth potential and risk.
• Right now, ArriVent BioPharma holds a valuation score of 3/6. This means it screens as undervalued on half of the checks used. The next sections will break this down using several valuation approaches, before looking at an even more powerful way to frame that valuation story.

Approach 1: ArriVent BioPharma Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow model takes projected future cash flows and discounts them back to today to estimate what the entire business could be worth right now.

For ArriVent BioPharma, the latest twelve month Free Cash Flow (FCF) is a loss of $160.6 million. Analyst and extrapolated projections suggest FCF remains negative over the next few years, moving from a forecast loss of $146 million in 2026 to a positive $102.6 million by 2030, then continuing higher through 2035. Simply Wall St uses a 2 Stage Free Cash Flow to Equity model, with analyst estimates up to 2030 and extrapolated growth thereafter.

When all these projected cash flows are discounted back to today, the model arrives at an estimated intrinsic value of about $153.23 per share. Compared with the recent share price around $22.86, this indicates the stock appears 85.1% undervalued according to this DCF view.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests ArriVent BioPharma is undervalued by 85.1%. Track this in your watchlist or portfolio, or discover 49 more high quality undervalued stocks.

Approach 2: ArriVent BioPharma Price vs Book

For early or unprofitable biopharma companies, price based metrics that rely on earnings are often less helpful, so investors frequently look at Price to Book, or P/B, to see how the market values the company relative to its net assets.

In general, a higher “normal” or “fair” P/B ratio tends to align with stronger growth expectations and a willingness to accept higher risk, while a lower ratio is more typical where growth is modest or uncertainty is higher.

ArriVent BioPharma is currently trading on a P/B ratio of 3.29x. This sits above the Biotechs industry average P/B of 2.50x and below the peer group average of 17.27x. On the surface, that places the stock somewhere between typical sector pricing and more highly valued peers.

Simply Wall St’s Fair Ratio is a proprietary estimate of what P/B might be reasonable for ArriVent BioPharma after factoring in elements such as earnings growth profile, profit margins, risk indicators, industry category and market capitalization. Because it is tailored to the company’s own fundamentals, this Fair Ratio can provide a more targeted reference point than broad peer or industry comparisons alone.

At present, there is no Fair Ratio figure available for ArriVent BioPharma, so it is not possible to draw a firm conclusion by comparing it directly with the current 3.29x P/B multiple.

Result: ABOUT RIGHT

P/B ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 20 top founder-led companies.

Upgrade Your Decision Making: Choose your ArriVent BioPharma Narrative

Earlier it was mentioned that there is an even better way to understand valuation, so Narratives are worth introducing as a simple tool that lets you spell out the story you see for a company, then tie that story to your own assumptions for future revenue, earnings, margins and a fair value estimate.

A Narrative connects three pieces in a clear line: what you think ArriVent BioPharma is trying to achieve, how that might shape its financials over time, and what that could make the shares worth compared with today’s US$22.86 price.

On Simply Wall St, Narratives sit in the Community page used by millions of investors. They can help you decide whether ArriVent BioPharma looks interesting by comparing each Narrative’s Fair Value with the current market price and seeing how that gap changes as new news or earnings updates flow through the model automatically.

For example, one ArriVent BioPharma Narrative might set a relatively conservative fair value with cautious revenue expectations, while another could assume stronger uptake for the pipeline and arrive at a much higher fair value. You can then decide which story feels more realistic for your own decision making.

Do you think there's more to the story for ArriVent BioPharma? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.